Coya Therapeutics (COYA) Income Statement

Coya Therapeutics reported revenue of $7.95M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 123.6% from $3.55M a year earlier. Coya Therapeutics posted a net loss of $21.23M, compared with a net loss of $14.88M a year earlier. Gross margin was 100.0% and operating margin -283.9%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $243.75K, up 49.0% from the same quarter a year earlier.

Coya Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Coya Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	7.95	3.55	6.00	0.00	0.00	0.00
Cost of Revenue	16.73	11.87	5.50	4.41	0.00	0.00
Gross Profit	7.95	3.55	0.50	-4.41	0.00	0.00
Operating Expenses
Research & Development	19.02	11.87	6.04	4.41	2.54	0.04
Selling, General & Administrative	11.45	8.89	7.83	4.85	2.31	0.67
Operating Expenses	30.50	20.80	13.91	9.81	4.87	0.70
Operating Income	-22.56	-17.25	-7.90	-9.81	-4.87	-0.70
Other Income/Expense
Interest Income	0.00	1.65	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00	-0.06
Other Income/Expense	1.33	1.65	0.64	-2.43	-0.02	0.00
Income
Income Before Tax	-21.22	-15.60	-7.26	-12.24	-4.89	-1.10
Income Tax Expense	0.00	-0.72	0.72	0.00	0.00	0.00
Net Income	-21.23	-14.88	-7.99	-12.24	-4.89	-1.10
Net Income - Continuous Operations	-21.23	-14.88	-7.99	-12.24	-4.89	-1.10
Net Income - Discontinued Operations	-	-	-	-	-	-
EBITDA	-22.53	-17.20	-7.88	-9.26	-4.85	0.00
EBIT	-22.56	-17.22	-7.90	-9.29	-4.87	-0.70
Depreciation & Amortization	0.03	0.03	0.03	0.03	0.02	0.70
Earnings Per Share
Basic EPS	-1.00	-1.00	-1.00	-5.00	-2.00	-1.00
Diluted EPS	-1.00	-1.00	-1.00	-5.00	-2.00	-1.00
Basic Shares Outstanding	16.73	15.24	10.16	2.59	2.59	1.84
Diluted Shares Outstanding	16.73	15.24	10.16	2.59	2.59	1.84

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Coya Therapeutics Financial Statements

What was Coya Therapeutics's revenue in fiscal 2025?

Coya Therapeutics reported revenue of $7.95M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 123.6% from $3.55M a year earlier.

Is Coya Therapeutics profitable?

No. Coya Therapeutics reported a net loss of $21.23M in fiscal 2025. In fiscal 2024 it lost $14.88M.

What is Coya Therapeutics's operating margin?

Coya Therapeutics's operating income was −$22.56M on revenue of $7.95M in fiscal 2025, an operating margin of -283.9%, compared with -485.4% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition